These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 11408918)
21. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Jagadeesh S; Kyo S; Banerjee PP Cancer Res; 2006 Feb; 66(4):2107-15. PubMed ID: 16489011 [TBL] [Abstract][Full Text] [Related]
22. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703 [TBL] [Abstract][Full Text] [Related]
23. A novel human cell culture model for the study of familial prostate cancer. Yasunaga Y; Nakamura K; Ewing CM; Isaacs WB; Hukku B; Rhim JS Cancer Res; 2001 Aug; 61(16):5969-73. PubMed ID: 11507036 [TBL] [Abstract][Full Text] [Related]
24. [Telomerase gene antisense oligodeoxynucleotide down-regulates telomerase activity in HL-60 cells]. He DM; Zhang H Ai Zheng; 2002 Oct; 21(10):1070-4. PubMed ID: 12508645 [TBL] [Abstract][Full Text] [Related]
25. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo]. Chen XJ; Zheng W; Chen LL; Chen ZB; Wang SQ Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1721-5. PubMed ID: 15569435 [TBL] [Abstract][Full Text] [Related]
26. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model. Canales BK; Li Y; Thompson MG; Gleason JM; Chen Z; Malaeb B; Corey DR; Herbert BS; Shay JW; Koeneman KS Urol Oncol; 2006; 24(2):141-51. PubMed ID: 16520278 [TBL] [Abstract][Full Text] [Related]
27. Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. Beisner J; Dong M; Taetz S; Nafee N; Griese EU; Schaefer U; Lehr CM; Klotz U; Mürdter TE Lung Cancer; 2010 Jun; 68(3):346-54. PubMed ID: 19695733 [TBL] [Abstract][Full Text] [Related]
28. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668 [TBL] [Abstract][Full Text] [Related]
29. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Patel MM; Parekh LJ; Jha FP; Sainger RN; Patel JB; Patel DD; Shah PM; Patel PS Head Neck; 2002 Dec; 24(12):1060-7. PubMed ID: 12454944 [TBL] [Abstract][Full Text] [Related]
30. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Botchkina GI; Kim RH; Botchkina IL; Kirshenbaum A; Frischer Z; Adler HL Clin Cancer Res; 2005 May; 11(9):3243-9. PubMed ID: 15867219 [TBL] [Abstract][Full Text] [Related]
31. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Chen Z; Koeneman KS; Corey DR Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918 [TBL] [Abstract][Full Text] [Related]
32. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Koga S; Kondo Y; Komata T; Kondo S Gene Ther; 2001 Apr; 8(8):654-8. PubMed ID: 11320413 [TBL] [Abstract][Full Text] [Related]
33. KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells. Phatak P; Dai F; Butler M; Nandakumar MP; Gutierrez PL; Edelman MJ; Hendriks H; Burger AM Clin Cancer Res; 2008 Jul; 14(14):4593-602. PubMed ID: 18628474 [TBL] [Abstract][Full Text] [Related]
34. [Antisense oligodeoxynucleotides of human telomerse catalytic sub-unit inhibits telomerase activity and proliferation in SKOV3 and COC1]. Yuan B; Mi R Zhonghua Fu Chan Ke Za Zhi; 2002 Apr; 37(4):198-201. PubMed ID: 12133408 [TBL] [Abstract][Full Text] [Related]
35. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Saretzki G; Ludwig A; von Zglinicki T; Runnebaum IB Cancer Gene Ther; 2001 Oct; 8(10):827-34. PubMed ID: 11687906 [TBL] [Abstract][Full Text] [Related]
36. [Inhibition of anti-sense human telomerase reverse transcriptase (hTERT) retroviral vector on lung cancer cells]. Tian FJ; Wang ZY; Ma JY; Zhao YX; Lu W Ai Zheng; 2004 May; 23(5):545-9. PubMed ID: 15142451 [TBL] [Abstract][Full Text] [Related]
37. Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro. Hammamieh R; Chakraborty N; Das R; Jett M J Exp Ther Oncol; 2004 Oct; 4(3):195-202. PubMed ID: 15724839 [TBL] [Abstract][Full Text] [Related]
38. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. Chau MN; El Touny LH; Jagadeesh S; Banerjee PP Carcinogenesis; 2007 Nov; 28(11):2282-90. PubMed ID: 17615260 [TBL] [Abstract][Full Text] [Related]
39. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Kondo S; Kondo Y; Li G; Silverman RH; Cowell JK Oncogene; 1998 Jun; 16(25):3323-30. PubMed ID: 9681832 [TBL] [Abstract][Full Text] [Related]
40. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Wong SC; Yu H; Moochhala SM; So JB Anticancer Res; 2003; 23(1A):465-9. PubMed ID: 12680250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]